Ozempic-like weight loss drugs may protect against Alzheimer's
UC expert comments on new research to NBC News
The University of Cincinnati's Alberto Espay, MD, was featured in a NBC News article commenting on new research that found a weight loss drug similar to Ozempic appeared to slow cognitive decline in patients with mild Alzheimer’s disease.
The research, presented Tuesday at the Alzheimer’s Association International Conference in Philadelphia, focused on liraglutide, the active ingredient used in some GLP-1 drugs. GLP-1 agonists are a class of medications that includes the popular diabetes and weight loss drugs Ozempic and Wegovy.
The midstage clinical trial included about 200 people in the United Kingdom who got daily injections of either liraglutide or a placebo. After one year, cognitive decline in the patients who got liraglutide had slowed by as much as 18% compared to those who didn’t get the drug, based on the Alzheimer’s Disease Assessment Scale, which tracks the progression of the disease by assessing memory, language, skills, understanding and reasoning abilities.
Espay said the fact that GLP-1s appear to help protect the brain makes sense, as Alzheimer's is thought to be a "syndrome of many diseases caused by different biological, toxic or infectious exposures.”
“This looks promising," said Espay, professor of neurology in the UC College of Medicine and director and endowed chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the UC Gardner Neuroscience Institute. "If this is replicated in a phase 3 trial, it could become the first truly disease-modifying treatment in Alzheimer’s disease.”
Featured photo at top of liraglutide injection pen. Photo/Hailshadow/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.